Search - tctmd.com

Displaying 61 - 80 of 208

Sort: Relevancy | Date

Elevated Risks From Lp(a) Can Be Offset by Lower Lifetime LDL Cholesterol

News Conference News EAS 2022

Elevated Risks From Lp(a) Can Be Offset by Lower Lifetime LDL Cholesterol

Michael O'Riordan

May 26, 2022

Lp(a) Linked to ASCVD and Aortic Stenosis Regardless of CRP Level

News Conference News EAS 2022

Lp(a) Linked to ASCVD and Aortic Stenosis Regardless of CRP Level

Michael O'Riordan

May 24, 2022

ROSE Trial: CETP Inhibitor Shows Promise as Oral Add-on for LDL-Lowering

News Conference News EAS 2022

ROSE Trial: CETP Inhibitor Shows Promise as Oral Add-on for LDL-Lowering

Michael O'Riordan

May 24, 2022

Stepwise or Hammer Down? Experts Debate Best Approach to LDL-Lowering

News Conference News EAS 2022

Stepwise or Hammer Down? Experts Debate Best Approach to LDL-Lowering

Michael O'Riordan

May 24, 2022

Modest Effects, Safety Concerns Plague Vupanorsen in TRANSLATE-TIMI 70

News Conference News ACC 2022

Modest Effects, Safety Concerns Plague Vupanorsen in TRANSLATE-TIMI 70

Michael O'Riordan

April 07, 2022

APOLLO: Novel siRNA Injectable Cuts Lp(a) by Nearly 100% in Small Study

News Conference News ACC 2022

APOLLO: Novel siRNA Injectable Cuts Lp(a) by Nearly 100% in Small Study

Michael O'Riordan

April 03, 2022

ApoB Gains Ground as Best Lipid Predictor of MI Risk

News Conference News AHA 2021

ApoB Gains Ground as Best Lipid Predictor of MI Risk

Michael O'Riordan

November 22, 2021

An Oral PCSK9 Inhibitor? Early Data Show Safety, Big LDL Drops

News Conference News AHA 2021

An Oral PCSK9 Inhibitor? Early Data Show Safety, Big LDL Drops

November 15, 2021

No Benefit for Icosapent Ethyl, P2Y12 Inhibitors in Separate COVID-19 Trials

News Conference News AHA 2021

No Benefit for Icosapent Ethyl, P2Y12 Inhibitors in Separate COVID-19 Trials

November 15, 2021

Pharmacist-Led Intervention Slashes LDL and BP in 10,000 Patients

News Conference News AHA 2021

Pharmacist-Led Intervention Slashes LDL and BP in 10,000 Patients

Michael O'Riordan

November 13, 2021

New ESC Prevention Guidelines Focus on Tailored, Escalating Therapy

News Conference News ESC 2021

New ESC Prevention Guidelines Focus on Tailored, Escalating Therapy

Michael O'Riordan

September 03, 2021

No Attenuation in CVD Risk Reduction for Patients Treated to Very Low LDLs: FOURIER

News Conference News ESC 2021

No Attenuation in CVD Risk Reduction for Patients Treated to Very Low LDLs: FOURIER

Michael O'Riordan

September 02, 2021

Fixed-Dose Combo Therapy Slashes CVD Risk in Primary Prevention

News Conference News ESC 2021

Fixed-Dose Combo Therapy Slashes CVD Risk in Primary Prevention

Michael O'Riordan

August 31, 2021

Central and Eastern Europe Failing to Achieve LDL Treatment Targets: DA VINCI

News Conference News EAS 2021

Central and Eastern Europe Failing to Achieve LDL Treatment Targets: DA VINCI

Michael O'Riordan

June 07, 2021

Lp(a) Not Associated With Ongoing Aortic Valve Calcification

News Conference News EAS 2021

Lp(a) Not Associated With Ongoing Aortic Valve Calcification

Michael O'Riordan

June 04, 2021

For High-Risk Patients Getting Evolocumab in Europe, Other Meds Fall Short

News Conference News EAS 2021

For High-Risk Patients Getting Evolocumab in Europe, Other Meds Fall Short

Michael O'Riordan

June 03, 2021

New STRENGTH Analysis Revives Omega-3 Debate

News Conference News ACC 2021

New STRENGTH Analysis Revives Omega-3 Debate

May 20, 2021

Evinacumab Lowers Triglycerides in Severe Hypertriglyceridemia

News Conference News ACC 2021

Evinacumab Lowers Triglycerides in Severe Hypertriglyceridemia

Yael L. Maxwell

May 16, 2021

Sacubitril/Valsartan Lowers Triglycerides in HFpEF: PARAGON-HF

News Conference News ACC 2021

Sacubitril/Valsartan Lowers Triglycerides in HFpEF: PARAGON-HF

Yael L. Maxwell

May 16, 2021

Social Determinants of Health Tied to Fewer COVID-19 Precautions in CVD Patients

News Conference News ACC 2021

Social Determinants of Health Tied to Fewer COVID-19 Precautions in CVD Patients

May 07, 2021

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.